ATHENS, Ohio--(BUSINESS WIRE)--Diagnostic HYBRIDS and ViroNovative BV have entered into a worldwide licensing agreement covering immunofluorescence-based diagnostic products for human metapneumovirus (hMPV). The non-exclusive agreement allows Diagnostic HYBRIDS to develop, manufacture, market, sell and distribute hMPV-specific antigen detection products upon receiving appropriate regulatory clearance for use in direct specimen detection and with cell culture.
